Protagonist Therapeutics, Inc.
NASDAQ:PTGXBiotechnology
+$1.72 today
- Market cap
- $8.30B
- Beta
- 1.83
- P/E (TTM)
- -64.2
- EPS (TTM)
- -$1.76
Volume 0.43M
Average 0.72M
PTGX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Protagonist Therapeutics, Inc.NASDAQ: PTGX
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin growth accelerates
Q2 FY2026 selling, general & admin of $12.65M rose 19.9% year over year, ahead of the +17.1% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 4.7% from the prior quarter. Over 3 fiscal years it compounded at +12.2% a year.
Context
- Selling, general & admin amounted to 97.5% of revenue in FY2025, up 87.5 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 9 analysts of $431.38M (+861.8%) for the fiscal year ending Dec 2026, a step up from the +3.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $12.65M-4.7% QoQ
- Last fiscal yearDec 2025
- $44.85M+3.2% YoY
- LTMJun 2026
- $48.49M+17.1% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 44.85M USD
- Year-over-year change
- +3.2%
- 4-year CAGR
- +13.3%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 44.85M | +3.2% |
| FY2024 | 2024-12-31 | 43.46M | +29.8% |
| FY2023 | 2023-12-31 | 33.49M | +5.5% |
| FY2022 | 2022-12-31 | 31.74M | +16.7% |
| FY2021 | 2021-12-31 | 27.2M | — |
Selling, General & Admin vs competitors
How PTGX compares with its peers on the latest reported figures
- PTGX's LTM Jun 2026 selling, general & admin of $48.49M is the 5th highest of the 7 companies compared; the peer median is $61.63M.
- Its year-over-year change of +17.1% is the 5th highest of 7, against a peer median of +30.5%.
- Selling, general & admin amounts to 17.2% of revenue for PTGX, versus a peer median of 168.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
IRONDisc Medicine, Inc. | LTM Sep 2026 | $82.59M | +51.8% | +67.0% | — |
| LTM Sep 2026 | $69.54M | -16.7% | +16.7% | 980.1% | |
| LTM Mar 2026 | $62.81M | +42.2% | +11.5% | 27.0% | |
| LTM Sep 2026 | $60.45M | +31.0% | +18.9% | 66.8% | |
| LTM Jun 2026 | $48.49M | +17.1% | +12.2% | 17.2% | |
| LTM Mar 2026 | $23.53M | +30.1% | +11.7% | — | |
| LTM Mar 2026 | $22.58M | +5.5% | -4.4% | 269.8% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding PTGX) | $61.63M | +30.5% | +14.2% | 168.3% | |
Competitors are the stored peer set for PTGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 27.36M | 26.58M | 60M | 434.43M | 46.02M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1.23M |
| Gross Profit | 27.36M | 26.58M | 60M | 434.43M | 44.79M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 97.3% |
| Research & Development | 126.01M | 126.22M | 120.16M | 138.13M | 159.29M |
| Selling, General & Admin | 27.2M | 31.74M | 33.49M | 43.46M | 44.85M |
| Operating Expenses | 153.2M | 157.95M | 153.65M | 181.59M | 202.92M |
| Depreciation & Amortization | 2.78M | 3.37M | 3.31M | 2.96M | 1.28M |
| EBITDA | (122.78M) | (124.02M) | (75.64M) | 282.37M | (128.03M) |
| EBITDA Margin | -448.8% | -466.6% | -126.1% | 65.0% | -278.2% |
| Operating Income | (125.85M) | (131.37M) | (93.65M) | 252.84M | (158.13M) |
| Operating Margin | -460.0% | -494.2% | -156.1% | 58.2% | -343.6% |
| Interest Income | 443K | 4.06M | 14.9M | 26.32M | 28.79M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 294K | 3.98M | 14.7M | 26.57M | 28.82M |
| Income Before Tax | (125.55M) | (127.39M) | (78.96M) | 279.41M | (129.31M) |
| Pre-Tax Margin | -458.9% | -479.3% | -131.6% | 64.3% | -281.0% |
| Income Tax Expense | 0 | 0 | 0 | 4.22M | 838K |
| Net Income | (125.55M) | (127.39M) | (78.96M) | 275.19M | (130.15M) |
| Net Margin | -458.9% | -479.3% | -131.6% | 63.3% | -282.8% |
| EPS (Basic) | (2.65) | (2.52) | (1.39) | 4.47 | (2.05) |
| EPS (Diluted) | (2.65) | (2.52) | (1.39) | 4.23 | (2.05) |
| Weighted Avg Shares | 46.32M | 49.04M | 56.76M | 61.57M | 63.57M |
| Weighted Avg Shares (Diluted) | 46.32M | 49.04M | 56.76M | 65.08M | 63.57M |
Protagonist Therapeutics, Inc.
NASDAQ:PTGX
Intrinsic Alpha fair value
Locked
Current Price
$127.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.